All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Current management of glaucoma is aimed at establishing and maintaining a target intraocular pressure (IOP) for each patient and prostaglandin analogues are superior to beta-blockers in lowering IOP (25-30% vs. 20-25%).
Patients should be monitored for any changes to eye colouration since an increase in the brown pigment in the iris may occur. Particular care is required in those with mixed coloured iris and those receiving treatment to one eye only. The eyelashes may also to grow longer and increase the degree of skin pigmentation around the eyes. Patients should be counselled regarding this side effect.
Prostaglandin analogues have a comparatively low incidence of reported side effects though uveitis and macular oedema have been reported.
Due to the increased cost preservative-free preparations should only be used in patients who have a proven sensitivity to preservatives. For further information please see
Administration of drugs to the eye
If prostaglandin analogues are used more frequently than the licensed once daily dose, this can cause the IOP to rise. One bottle is designed to last for 28 days when used in either one or both eyes.
Although all treatments for glaucoma are listed as specialist initiated drugs it is expected that the first-line treatment to be with generic latanoprost.
Where patients require treatment with a prostaglandin analogue and a beta blocker or a sympathomimetic, combination products may be used if this will aid compliance and may be useful in patients with poor manual dexterity, and patients who experience local irritation due to increased exposure to preservatives.
Dose
Dose
Dose
Dose
Dose
Dose
Dose
Dose